Our decision was triggered by positive results from previous reports in PC-3 models that highlighted the theragnostic potential of [67/68Ga/111In/177Lu]NeoBOMB1 radioligands in prostate cancer and by the excellent visualization capacity of [68Ga]NeoBOMB1 in GRPR-positive lesions in prostate cancer patients [19,20]. The gene discussed is GRPR; the disease is prostate carcinoma.